Osteonecrosis of the jaw: BRONJ and ARONJ
2014; Royal College of Surgeons of England; Volume: 5; Issue: 2 Linguagem: Inglês
10.1308/204268514x13939420839188
ISSN2042-6860
Autores Tópico(s)Cancer Diagnosis and Treatment
ResumoBisphosphonates and other more recent antiresorptive agents are potent inhibitors of osteoclast function and osteoclast-mediated bone resorption. As such, they have been effectively utilised to reduce skeletally related events and improve the quality of life of patients with osteoporosis and malignant osteolytic disease. Despite these benefits, osteonecrosis of the jaw continues to be a worrisome complication in a small subset of patients receiving these drugs.
Referência(s)